John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.
